ArriVent BioPharma (AVBP) Competitors

ArriVent BioPharma (NASDAQ:AVBP) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and community ranking.

Do institutionals and insiders hold more shares of AVBP or XENE?

9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 95.4% of Xenon Pharmaceuticals shares are held by institutional investors. 5.5% of Xenon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has better earnings & valuation, AVBP or XENE?

ArriVent BioPharma has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$69.33M	-$3.77	-5.53
Xenon Pharmaceuticals	$7.50M	321.57	-$182.39M	-$3.23	-9.73

Do analysts rate AVBP or XENE?

ArriVent BioPharma currently has a consensus price target of $39.29, indicating a potential upside of 88.33%. Xenon Pharmaceuticals has a consensus price target of $54.82, indicating a potential upside of 74.41%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, equities analysts plainly believe ArriVent BioPharma is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Xenon Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor AVBP or XENE?

In the previous week, Xenon Pharmaceuticals had 28 more articles in the media than ArriVent BioPharma. MarketBeat recorded 48 mentions for Xenon Pharmaceuticals and 20 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 0.64 beat Xenon Pharmaceuticals' score of 0.49 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	13 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk & volatility, AVBP or XENE?

ArriVent BioPharma has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.

Is AVBP or XENE more profitable?

Xenon Pharmaceuticals' return on equity of -24.69% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-43.89%	-29.67%
Xenon Pharmaceuticals	N/A	-24.69%	-23.68%

Does the MarketBeat Community believe in AVBP or XENE?

Xenon Pharmaceuticals received 409 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 69.79% of users gave Xenon Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
ArriVent BioPharma	Outperform Votes 23 100.00%	Underperform Votes No Votes
Xenon Pharmaceuticals	Outperform Votes 432 69.79%	Underperform Votes 187 30.21%

Summary

Xenon Pharmaceuticals beats ArriVent BioPharma on 9 of the 17 factors compared between the two stocks.